ArticleCureus2024
Efficacy of Aspirin in Preventing Venous Thromboembolism in Total Knee and Hip Joint Replacement.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a significant complication following total knee arthroplasty (TKA) and total hip arthroplasty (THA). Aspirin has gained attention as a cost-effective, safe alternative to traditional anticoagulants like enoxaparin, but comparative data on efficacy and safety remain limited.
methodsThis randomized controlled trial compared the efficacy of aspirin and enoxaparin in preventing VTE following TKA and THA. A total of 60 patients were recruited, with 30 patients in each group. Prophylactic efficacy was assessed through Doppler ultrasonography preoperatively and at two and four weeks postoperatively. The primary outcome was the incidence of VTE or bleeding events within 90 days. Results: No cases of symptomatic deep vein thrombosis, pulmonary embolism, or other thrombotic events were observed in either group during the 90-day follow-up. Additionally, no statistically significant differences were noted between groups for bleeding events, including hematoma or hemarthrosis. Both treatments were well tolerated, with comparable safety profiles. Systemic and gastrointestinal complications were minimal and evenly distributed across groups.
conclusionOur findings suggest that aspirin and enoxaparin are equally effective in preventing VTE after total knee or hip arthroplasty. Further research is needed to determine the optimal duration and dosage of aspirin for VTE prophylaxis in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.